News
Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.65% to $604.62 Wednesday, on what proved to be an all-around dismal ...
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback